Titan Spine Raises Capital to Support nanoLOCK Interbody Fusion Devices
Titan Spine closed a substantial round of financing for an undisclosed amount with its investor, Southlake Equity. Proceeds will support U.S. sales expansion and surgeon adoption of Endoskeleton® titanium interbody fusion implants and launch of next-generation nanoLOCK™ surface technology.
The company just announced the creation of a new technology ICD-10 code for a nanotextured surface on an interbody fusion device. Titan Spine’s nanoLOCK technology has been given access to use this code, beginning 4Q16.
Sources: Titan Spine LLC, ORTHOWORLD Inc.